• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Pitch a Startup
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a $100 million Series B financing

November 7, 2019 By admin Leave a Comment

The financing was led by Fresenius Medical Care Ventures (FMCV), with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors, including, but not limited to, ARCH Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures, all participated.

eGenesis is committed to helping solve the global organ shortage by pioneering an alternative source of human-compatible organs. It is currently estimated that there are between 1.5 to 2 million people on the organ transplant waitlist globally. This financing will enable the acceleration of the eGenesis kidney xenotransplant program into the clinic, as well as support advancement of a range of other xenotransplant programs across islet cell, liver, heart, and lung. The focus of the company is to rapidly advance an entirely new set of options across the transplantation field.

“Leaps by Bayer” is built for the specific purpose of tackling fundamental breakthrough solutions in the fields of health and nutrition with the help of new technologies. Sustainable organ replacement is one of the ten areas of engagement and investment (called “leaps”) for Leaps by Bayer. “We believe eGenesis is poised to revolutionize the entire organ transplantation market. This could save lives in a way that was previously not thought possible just a few years ago,” noted Jürgen Eckhardt, Head of Leaps by Bayer. Eckhardt and Dr. Lucio Iannone will represent Leaps by Bayer by actively participating on the eGenesis Board of Directors.

“eGenesis has a bold vision to solve the organ shortage crisis through xenotransplantation,” said Paul Sekhri, president and chief executive officer of eGenesis. “As we look ahead, we are proud to partner with Leaps by Bayer who has demonstrated a commitment for ushering in paradigm-shifting advances in the life sciences that will bring forward tomorrow’s medicines.”

Kemal Malik, Member of the Board of Management, Bayer AG, and responsible for Innovation, added, “Within Bayer’s innovation strategy, Leaps is driving breakthrough invention at Bayer and the eGenesis approach represents a truly transformational option, addressing the unmet medical need of patients suffering from a disease where organ transplantation could be a potentially lifesaving treatment.”

Leaps by Bayer, a unit of Bayer, is investing in solutions to some of today’s biggest challenges in health and agriculture. Previous Leaps investments into potentially breakthrough technologies include Casebia Therapeutics (Cure genetic diseases), BlueRock Therapeutics (Regenerate lost tissue function), Joyn Bio (Reduce environmental impact of farming) as well as Khloris, Century Therapeutics and Pyxis Oncology (Prevent and cure cancer).

About Transplantation and Xenotransplantation
The demand for lifesaving organs far outnumbers available supply. In the U.S. today, 20 people die every day due to lack of available organs for transplant and every 10 minutes an additional name is added to the national transplant waitlist. There are more than 113,000 people in need of a lifesaving organ transplant in the U.S. alone. Globally, there are an estimated 1.5 to 2 million people on an organ waitlist.

The concept of xenotransplantation, or the transplantation of organs, tissue and cells from one species into another, has been explored for several decades, with the pig considered the most suitable donor for humans. However, until the development of modern gene editing tools, incompatibilities related to virology and immunology have prevented porcine organ xenotransplantation from entering clinical development.

About eGenesis
eGenesis’ goal is to make available safe and reliable xeno organs, tissues, and cells to patients in need and advance the field of transplantation. eGenesis uses gene editing tools, such as CRISPR, to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. eGenesis is advancing an initial product toward the clinic for kidney transplant, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy. Learn more at egenesisbio.com.

Filed Under: PR Tagged With: Transplantation, Xenotransplantation

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Another pandemic may be on the horizon: antimicrobial resistance
New Technologies to Disrupt Traditional Renewable Fuels
Wearable IoTs
Critical Mineral Shortages Could Disrupt Global Supply Chains
Coal-powered electricity reached an all-time high in 2021
Solar and wind costs are now competitive with fossil fuels
European Market for Veterinary Antibiotics

Market Research Media

NFTmediamarketplace.com (NFT Media Marketplace): Who’s making the most money on the NFT boom?
AfricanInvesting.com (African Investing): Africa VC Funding Grew Exponentially in 2016-2021
PublicDonmain.ai: You can’t copyright AI-created art
NoSQLdatabase.com: SQL versus NoSQL overview
InfluenceMgmt.com (Influence Management): Formal vs Informal Influence
AI will contribute $15.7 trillion to the global economy by 2030
ReleaseWealth.com (Release Wealth): Modern Philanthropy is Technology-Based

Secondary Sidebar

Technologies

Infinitum Electric Raises $80M in Series D Funding Led by Riverstone Holdings to Scale Production of Sustainable Motors
Organizations are using a wider range of intelligent automation technologies
IDC FutureScape: Top 10 Predictions for the Future of Intelligence
Samsung Unveils ISOCELL Image Sensor with Industry’s Smallest 0.56μm Pixel
Trends in data and analytics

Tech Events

DesignCon 2021, August 16-18, 2021, San Jose McEnery Convention Center
KubeCon+CloudNativeCon, October 11-15, 2021, in person in Los Angeles or virtually
TiEcon 2021, May 6-8, 2021
SIGGRAPH 2021, 9-13 August, 2021
The RISC-V Summit will be held at Moscone West in San Francisco from December 6-8, 2021

Footer

Recent Posts

  • Breakthrough VR Basketball App Gym Class Closes $8 Million in Seed Round Led by Andreessen Horowitz
  • Techstars and Audi Launch Pre-Accelerator Program to Promote Innovation in Mobility
  • Latchel Closes $16.7 Million to Enhance Resident Services and Maintenance Workflow
  • Seedtag raises over €250M from Advent International
  • Arable Raises $40 Million to Accelerate Sustainable Agriculture
  • European Quantum Computing Leader IQM Raises €128m Led by World Fund to Help Combat the Climate Crisis
  • Whatnot raises $260M Series D co-led by DST Global and CapitalG to expand its live, social commerce marketplace
  • ZeroAvia Secures Additional $30 Million in Funding from IAG, Barclays, NEOM & AENU
  • Medusa Raises $8m to Build the Leading E-Commerce Platform for Developers
  • Blue Ocean Barns Completes $20 Million Series A Financing, Accelerating Solution to Agricultural Methane Emissions

Dossier

Microsoft acquires privileged access management vendor CloudKnox Security
Xilinx Acquires Silexica to Broaden its Developer Base
IBM Appoints Martin Schroeter as CEO of “NewCo” Independent Managed Infrastructure Services Business to Spin Out from IBM
Defense & Cybersecurity Digest
Clean Shipping: Berge Bulk and Kongsberg Maritime join forces to advance marine decarbonisation

Press Media Release

Adorama Business Solutions Launches Federal Government Purchasing Portal
How to Write a Press Release Reporters Will Actually Read
Woolpert Fully Reopens Offices in North America; Employees Offered Flexible Schedules
Kyodo News Images (KI) Launches New and Improved Online Sales Platform “Image Link Global (ILG)”
Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea

App Coding

Platform.sh Secures $140 million in Series D Funding to Support Enterprises in Scaling Fleets of Websites and Applications
Registered yet for Cloudflare Connect London 2022?
Zype Releases New Feature-Rich Apps Creator for OTT
Coder Announces First Multi-Cloud, Multi-Compute Integrated Development Environment Platform
New app to help northeastern Illinois drivers avoid traffic and earn rewards for improving their commute

API Coding

Apiip Expand IP To Location API Services to Verify 1 million+ Requests A Month
DataGrail Launches API & Agent to Automate DSR Fulfillment Across All Internal Data Systems, Saving Companies Weeks of Engineering Time
What is a REST API?
Apiiro Extends Right from Code to Runtime To Help Developers Fix Risks Faster
Most commonly used HTTP Headers

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT